Collette Odibo, APRN
Psychiatric/Mental Health · Washington, DCNPI 1255661294
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Lundbeck LLC at 24.8% of the total. 2025 is the largest year on record at $1,242, 5.4 times the $228 reported in 2021. Among psychiatric/mental health clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$856
- AbbVie$751
- Otsuka America Pharmaceutical, Inc.$552
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$372
- Vanda Pharmaceuticals Inc.$273
- E.r. Squibb & Sons, L.L.C.$211
- plus $433 from 5 others
What the payments were for
- Food & beverage$3,450100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 42 | $856 |
| AbbVie | 39 | $751 |
| Otsuka America Pharmaceutical, Inc. | 31 | $552 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $372 |
| Vanda Pharmaceuticals Inc. | 9 | $273 |
| E.r. Squibb & Sons, L.L.C. | 9 | $211 |
| Alkermes, Inc. | 7 | $163 |
| Neurocrine Biosciences, Inc. | 7 | $140 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| Johnson & Johnson | 1 | $42 |
| Harmony Biosciences LLC | 1 | $36 |
How this compares
$3,450 in reported general payments places this provider in the 90th percentile of 137 psychiatric/mental health providers in District of Columbia.
See all psychiatric/mental health providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 12 | $178 |
| Buspirone Hcl | 19 | $164 |
| Bupropion Hcl SrBupropion Hcl | 13 | $144 |
| Memantine Hcl | 11 | $55 |
| Quetiapine Fumarate | 15 | $45 |
| Sertraline Hcl | 16 | $41 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Washington
- Erin WalczykowskiWashington$349K
- Caroline BonuWashington$16K
- Miriam EzenwakaWashington$6K
- Orin GreeneWashington$4K
- Hope AchoronyeWashington$4K
- Samantha HyltonWashington$4K
- Nkechi OnwucheWashington$4K
- Emmanuel Kamdem SangoWashington$4K
- Arithia HardenWashington$4K
- Zion DestaWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.